Same Genes linked to Early- and Late-Onset
Alzheimer’s
Newswise, February 5, 2012 — The same gene
mutations linked to inherited, early-onset
Alzheimer’s disease have been found in
people with the more common late-onset form
of the illness.
The discovery by researchers at Washington
University School of Medicine in St. Louis
may lead doctors and researchers to change
the way Alzheimer’s disease is classified.
They report their findings Feb. 1 in the
online journal PLoS One(Public
Library of Science).
“We probably shouldn’t think of early-onset
disease as inherited and late-onset as
sporadic because sporadic cases and familial
clustering occur in both age groups,” says
senior investigator Alison M. Goate, DPhil.
“I think it’s reasonable to assume that at
least some cases among both early- and
late-onset disease have the same causes. Our
findings suggest the disease mechanism can
be the same, regardless of the age at which
Alzheimer’s strikes. People who get the
disease at younger ages probably have more
risk factors and fewer protective ones,
while those who develop the disease later in
life may have more protective factors, but
it appears the mechanism may be the same for
both.”
The researchers used next-generation DNA
sequencing to analyze genes linked to
dementia.
They sequenced the APP (amyloid precursor
protein) gene, and the PSEN1 and PSEN2
(presenilin) genes. Mutations in those genes
have been identified as causes of
early-onset Alzheimer’s disease.
They also sequenced the MAPT (microtubule
associated protein tau) gene and GRN
(progranulin) gene, which have been
associated with inherited forms of another
illness involving memory loss called
frontotemporal dementia.
“We found an increase in rare variants in
the Alzheimer’s genes in families where four
or more members were affected with
late-onset disease,” says Goate, the Samuel
and Mae S. Ludwig Professor of Genetics in
Psychiatry, professor of neurology, of
genetics and co-director of the Hope Center
Program on Protein Aggregation and
Neurodegeneration.
“Changes in these genes were more common in
Alzheimer’s cases with a family history of
dementia, compared to normal individuals.
This suggests that some of these gene
variants are likely contributing to
Alzheimer’s disease risk.”
The study also found mutations in the MAPT
and GRN genes in some Alzheimer’s patients,
suggesting they had been incorrectly
diagnosed as having Alzheimer’s disease when
they instead had frontotemporal dementia.
Goate and her colleagues studied the five
genes in members of 440 families in which at
least four individuals per family had been
diagnosed with Alzheimer’s disease.
They found rare variants in key
Alzheimer’s-related genes in 13 percent of
the samples they analyzed.
“Of those rare gene variants, we think about
5 percent likely contribute to Alzheimer’s
disease,” says first author Carlos Cruchaga,
PhD, assistant professor of psychiatry.
“That may not seem like a lot, but so many
people have the late-onset form of
Alzheimer’s that even a very small
percentage of patients with changes in these
genes could represent very large numbers of
affected individuals.”
Goate, who in 1991 was the first scientist
to identify a mutation in the APP gene
linked to inherited, early-onset Alzheimer’s
disease, now wants to look closely at
families with multiple cases of Alzheimer’s
but no mutations in previously identified
Alzheimer’s genes.
She says it’s likely they carry mutations in
genes that scientists don’t yet know about.
And she believes that new sequencing
techniques could speed the discovery of
these genes. In fact, the researchers say a
study like this would have been impossible
only a few years ago.
“With next-generation sequencing technology,
it’s now possible to sequence all of these
genes at the same time,” Cruchaga says. “One
reason we didn’t do this study until now is
that 15 to 20 years ago when these genes
were first identified, it would have taken
years to sequence each gene individually.”
Cruchaga and Goate say the new technology
and their new findings suggest that it may
be worthwhile to sequence these genes in
people with a strong family history of
Alzheimer’s disease.
“We would like to see physicians who treat
patients with late-onset disease ask
detailed questions about family history,”
Goate says. “I’m sure many probably do that
already, but in those families with very
strong histories, it’s not unreasonable to
think about screening for genetic
mutations.”
She says such screenings also may weed out
people thought to have Alzheimer’s disease
who actually have changes in genes related
to frontotemperal dementia.
Both Goate and Cruchaga agree that one
result of their discovery that the same
genes can be connected with both early- and
late-onset forms of Alzheimer’s disease may
be changes in the way the disease is
classified.
“It’s always been somewhat arbitrary,
figuring out where early-onset ends and
late-onset begins,” Goate says. “So I no
longer look at early- and late-onset disease
as being different illnesses. I think of
them as stages along a continuum.”
Cruchaga C, et al, Rare variants in APP,
PSEN1 and PSEN2 increase risk for AD in
late-onset Alzheimer’s disease families.PLoS
One, Feb. 1, 2012.http://dx.plos.org/10.1371/journal.pone.0031039
Funding for this research comes from grants
awarded by the National Institute on Aging
(NIA) of the National Institutes of Health
(NIH) and by the Barnes-Jewish Hospital
Foundation. Much of the genetic material
studied came from the NIA’s Late-Onset
Alzheimer’s Disease (NIA-LOAD) Family Study.
Researchers also studied samples from the
National Cell Repository for Alzheimer’s
Disease, which receives government support
under a cooperative agreement grant awarded
by the National Institute on Aging.
Washington University School of Medicine’s
2,100 employed and volunteer faculty
physicians also are the medical staff of
Barnes-Jewish and St. Louis Children’s
hospitals.
The School of Medicine is one of the leading
medical research, teaching and patient care
institutions in the nation, currently ranked
fourth in the nation by U.S. News & World
Report. Through its affiliations with
Barnes-Jewish and St. Louis Children’s
hospitals, the School of Medicine is linked
to BJC HealthCare.